Section Arrow
RPRX.NASDAQ
- Royalty Pharma plc
Quotes are at least 15-min delayed:2025/04/14 04:54 EDT
Last
 31.95
+0.74 (+2.37%)
Day High 
32.005 
Prev. Close
31.21 
1-M High
34.14 
Volume 
5.90M 
Bid
29.1
Ask
33
Day Low
30.96 
Open
31.44 
1-M Low
29.66 
Market Cap 
13.52B 
Currency USD 
P/E 16.34 
%Yield 2.66 
10-SMA 31.32 
20-SMA 32.19 
50-SMA 32.47 
52-W High 34.2 
52-W Low 24.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.91/3.71
Enterprise Value
20.14B
Balance Sheet
Book Value Per Share
16.03
Cash Flow
Cash Flow Yield
0.15
Income Statement
Total Revenue
2.26B
Operating Revenue Per Share
5.36
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed:2025/04/14 04:54 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.